Send to

Choose Destination
See comment in PubMed Commons below
Zhongguo Fei Ai Za Zhi. 2013 Dec;16(12):663-70. doi: 10.3779/j.issn.1009-3419.2013.12.09.

[Clinical significance of ROS1 rearrangements in non-small cell lung cancer].

[Article in Chinese]

Author information

  • 1Cell Signaling Technology China Branch, Shanghai 200120, China.


in English, Chinese

Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase gene have recently been described in multiple malignancies, including non-small cell lung cancer (NSCLC). ROS1 rearrangement defines a new molecular subset of NSCLC with the prevalence of ROS1 rearrangements around 1%-2%. ROS1-positive NSCLCs arise in young never-smokers with adenocarcinoma that are similar to those observed in patients with ALK-rearranged NSCLC. Crizotinib demonstrates in vitro activity and early clinical trial shows marked antitumor activity in ROS1-rearranged patients. The overall response rate is around 56% and the disease control rate at 8 weeks is about 76%. Further understanding the ROS1 fusions in the pathogenesis of NSCLC, methods to detect ROS1 rearrangements, and targeting ROS1-rearranged NSCLC patients with specific kinase inhibitors would lead to an era of personalized medicine.

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Editorial Office of Chinese Journal of Lung Cancer
    Loading ...
    Write to the Help Desk